Display options
Cite
Raciborski F, Śliwczyński A, Kłak A, et al. Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system - the case of Poland. Reumatologia. 2016;54(6):278-284doi: 10.5114/reum.2016.64902.
Raciborski, F., Śliwczyński, A., Kłak, A., Kwiatkowska, B., Brzozowska, M., & Tłustochowicz, M. (2016). Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system - the case of Poland. Reumatologia, 54(6), 278-284. https://doi.org/10.5114/reum.2016.64902
Raciborski, Filip, et al. "Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system - the case of Poland." Reumatologia vol. 54,6 (2016): 278-284. doi: https://doi.org/10.5114/reum.2016.64902
Raciborski F, Śliwczyński A, Kłak A, Kwiatkowska B, Brzozowska M, Tłustochowicz M. Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system - the case of Poland. Reumatologia. 2016;54(6):278-284. doi: 10.5114/reum.2016.64902. Epub 2016 Dec 30. PMID: 28115777; PMCID: PMC5241363.
Copy Download .nbib Format: NLM
Share it on

Reumatologia. 2016;54(6):278-284. doi: 10.5114/reum.2016.64902. Epub 2016 Dec 30.

Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system - the case of Poland.

Reumatologia

Filip Raciborski, Andrzej Śliwczyński, Anna Kłak, Brygida Kwiatkowska, Melania Brzozowska, Małgorzata Tłustochowicz

Affiliations

  1. Department of Gerontology and Public Health, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
  2. Department of Medical Standards, Procedures and Quality, Health Sciences Faculty, Medical University of Lodz, Poland Departament of Analyses and Strategy, Central Office of National Health Fund, Lodz, Poland.
  3. Clinic of Early Arthritis, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
  4. Department of Internal Medicine and Rheumatology, Military Institute of Medicine Warsaw, Poland.

PMID: 28115777 PMCID: PMC5241363 DOI: 10.5114/reum.2016.64902

Abstract

OBJECTIVE: The objective of the study was to analyse the prevalence of psoriatic arthritis (PsA) in Poland and to assess the costs generated by treatment of PsA patients in the system of public healthcare.

MATERIAL AND METHODS: The analysis was based on the database of the public payer, the National Health Fund (NFZ). PsA was defined by the diagnostic ICD-10 codes M07 (Enteropathic arthropathies) and L40.5 (Psoriatic arthropathies). The estimate of the costs was based on the reports submitted to the NFZ by health service providers. The prevalence rates were calculated using the NFZ data and the population estimates from the Central Statistical Office of Poland (GUS).

RESULTS: In 2015, the prevalence of PsA (ICD-10: L40.5 and M07) in Poland was 3.2 per 10 000 population (3.7 in women and 2.6 in men). In 2015, nearly 7.3 thousand patients with the diagnosis of M07 and 6.3 thousand patients with the diagnosis of L40.5 received healthcare benefits. Women accounted for 60.6% of those patients. Nearly three fourths of PsA patients were aged 40 to 69 years with the median age of 54 years (56 years in women and 50 years in men). Between 2008 and 2015 the NFZ expenditure on the treatment of PsA increased from 6.6 million Polish zloty (PLN) (1.9 million EUR) to PLN 50.8 million (12.1 million EUR). In the same period, the number of PsA patients increased from 3.4 thousand to 11.9 thousand. In 2015, the mean cost of treatment per PsA patient was PLN 3.8 thousand.

CONCLUSIONS: The PsA prevalence rates estimated by the authors from the NFZ database are clearly lower than those derived from studies in other European countries, which may suggest that the actual number of PsA patients in Poland may be underestimated. Still the number of patients treated for PsA increased nearly 3.5-fold during 2008-2015, when the cost of PsA treatment rose more than 7 times.

Keywords: epidemiology; increasing costs of treatment; psoriatic arthritis

References

  1. Clin Exp Rheumatol. 2008 Jan-Feb;26(1):125-8 - PubMed
  2. RMD Open. 2015 Jun 29;1(1):e000012 - PubMed
  3. Curr Rheumatol Rep. 2015 Feb;17(2):10 - PubMed
  4. PLoS One. 2013 May 15;8(5):e64155 - PubMed
  5. Curr Rheumatol Rep. 2015 Oct;17(10):64 - PubMed
  6. Ann Rheum Dis. 2012 Aug;71(8):1273-7 - PubMed
  7. PLoS One. 2014 May 29;9(5):e98024 - PubMed
  8. J Rheumatol Suppl. 2015 Nov;93:33-5 - PubMed
  9. Arthritis Rheum. 2009 Feb 15;61(2):233-9 - PubMed
  10. BMC Infect Dis. 2016 Mar 01;16:100 - PubMed
  11. Rheumatol Int. 2015 Aug;35(8):1361-7 - PubMed
  12. Ann Rheum Dis. 2014 Jan;73(1):212-8 - PubMed
  13. Scand J Rheumatol. 2004;33(5):318-22 - PubMed
  14. Rheumatology (Oxford). 2013 Mar;52(3):568-75 - PubMed
  15. BMC Musculoskelet Disord. 2010 May 26;11:98 - PubMed
  16. Ann Rheum Dis. 2008 May;67(5):677-82 - PubMed
  17. Arthritis Rheum. 2006 Aug;54(8):2665-73 - PubMed

Publication Types